Currently out of the existing stock ratings of Leland Gershell, 189 are a BUY (92.2%), 6 are a SELL (2.93%), 10 are a HOLD (4.88%).

Leland Gershell

Work Performance Price Targets & Ratings Chart

Analyst Leland Gershell, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 36.74% that have a potential upside of 37.79% achieved within 146 days.

Leland Gershell’s has documented 432 price targets and ratings displayed on 47 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VRDN, Viridian Therapeutics at 07-Aug-2025.

Wall Street Analyst Leland Gershell

Analyst best performing recommendations are on CAPR (CAPRICOR THERAPEUTICS).
The best stock recommendation documented was for CAPR (CAPRICOR THERAPEUTICS) at 9/23/2024. The price target of $15 was fulfilled within 7 days with a profit of $9.03 (151.26%) receiving and performance score of 216.08.

Average potential price target upside

of $162.2 (39.92%) on AMRN (AMARIN PLC).
of $87.89 (15.71%) on ARGX (ARGENX NV ADR).
of $59.61 (55.66%) on ASND (ASCENDIS PHARMA AS).

ACST Acasti Pharma ADMA ADMA Biologics AGRX Agile Thrpe ALNY Alnylam Pharmaceuticals AMRN Amarin PLC ASND Ascendis Pharma AS BMRN Biomarin Pharmaceutical BXRX Baudax Bio CASI CASI Pharmaceuticals CERC Cerecor CPRX Catalyst Pharmaceuticals EVFM Evofem Biosciences MGEN Viridian Therapeutics MIST Milestone Pharmaceuticals REPH Recro Pharma TARA Protara Therapeutics URGN UroGen Pharma Ltd VERU Veru BBI Brickell Biotech PLXP PLx Pharma CRXT Clarus Therapeutics Holdings HZNP Horizon Pharma PLC LUMO Lumos Pharma AVTX Avalo Therapeutics CLNN Clene TRVI Trevi Therapeutics XLRN Acceleron Pharma CRBP Corbus Pharmaceuticals EPZM Epizyme OTLK OUTLOOK THERAPEUTICS INC SLNO Soleno Therapeutics XFOR X4 Pharmaceuticals NCNA NuCana PLC TEVA Teva Pharma Industries Ltd ADR VRDN Viridian Therapeutics CRNX Crinetics Pharmaceuticals PDSB PDS Biotechnology Corp ARGX argenx NV ADR CAPR Capricor Therapeutics CMMB Chemomab Therapeutics Ltd DRC EPIX ESSA Pharma IMVT Immunovant LGND Ligand Pharmaceuticals SABS SAB Biotherapeutics CALC CalciMedica, Common Stock DNTH Dianthus Therapeutics ENGN enGene Holdings Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Oren Livnat (HC WAINWRIGHT)